Chistiakova V R
Vestn Otorinolaringol. 2004(2):9-12.
Betaserk treatment was given to 78 children aged 6 to 14 years suffering from acute or progressive neurosensory hypoacusis (n=62) and vestibulopathy (n=16). The best results were achieved in vestibulopathy in older children. Stable improvement of hearing in the range 10--20 dB was achieved in 16 (30.7%) children, stable hearing stabilization was seen in 32 (61.4%) cases. Betaserk was well tolerated, had no side effects. Thus, betaserk is effective in the treatment of children with vestibulopathy, acute and progressive neurosensory hypoacusis.
对78名6至14岁患有急性或进行性神经性听觉减退(n = 62)和前庭病(n = 16)的儿童进行了倍他司汀治疗。年龄较大的儿童在前庭病治疗中取得了最佳效果。16名(30.7%)儿童的听力稳定改善了10 - 20分贝,32例(61.4%)出现听力稳定。倍他司汀耐受性良好,无副作用。因此,倍他司汀对患有前庭病、急性和进行性神经性听觉减退的儿童有效。